The Kidney Transplant Rejection drugs in development market research report provides comprehensive information on the therapeutics under development for Kidney Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Kidney Transplant Rejection. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Kidney Transplant Rejection and features dormant and discontinued products.
GlobalData tracks 45 drugs in development for Kidney Transplant Rejection by 39 companies/universities/institutes. The top development phase for Kidney Transplant Rejection is preclinical with 13 drugs in that stage. The Kidney Transplant Rejection pipeline has 41 drugs in development by companies and four by universities/ institutes. Some of the companies in the Kidney Transplant Rejection pipeline products market are: Astellas Pharma, Cynata Therapeutics and Bristol-Myers Squibb.
The key targets in the Kidney Transplant Rejection pipeline products market include T Cell Specific Surface Glycoprotein CD28, CD40 Ligand, and T Lymphocyte Activation Antigen CD80.
The key mechanisms of action in the Kidney Transplant Rejection pipeline product include T Cell Specific Surface Glycoprotein CD28 Antagonist with three drugs in Phase III. The Kidney Transplant Rejection pipeline products include eight routes of administration with the top ROA being Intravenous and 13 key molecule types in the Kidney Transplant Rejection pipeline products market including Cell Therapy, and Monoclonal Antibody.
Kidney Transplant Rejection overview
Kidney transplantation is a therapy performed to replace a diseased kidney with a healthy kidney from another person. Risk factors associated with transplantation are bleeding, infection, blockage of the blood vessels to the new kidney, leakage of urine or blockage of urine in the ureter, and initial lack of function of the new kidney. Treatment includes immunosuppressive drugs to prevent organ rejection.
For a complete picture of Kidney Transplant Rejection’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
